Literature DB >> 3572746

Pharmacokinetic analysis of concentration data of drugs with irregular absorption profiles using multi-fraction absorption models.

K Murata, K Noda, K Kohno, M Samejima.   

Abstract

Nonlinear regression analysis of plasma drug concentration data with irregular or stepwise absorption profiles was studied using multi-fraction absorption models in which drugs in the gastrointestinal tract were assumed to be divided into several fractions each with its respective lag time and absorption rate constant. Plasma allopurinol concentration data, with two-phase absorption profiles in dogs after oral administration, were found to be satisfactorily fitted using a two-fraction absorption model. Plasma sulfisoxazole concentration data in humans were also successfully analyzed using a two-fraction absorption model. Plasma and urinary concentrations of pindolol in humans after oral administration of sustained-release preparations were fitted to two- or three-fraction absorption models. The pharmacokinetic absorption behavior of a sustained-release preparation of diltiazem hydrochloride was studied using a multi-fraction absorption model. Pharmacokinetic parameters derived from these models and those from the discontinuous absorption model were compared.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3572746     DOI: 10.1002/jps.2600760205

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  13 in total

1.  Time-dependent oral absorption models.

Authors:  K Higaki; S Yamashita; G L Amidon
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

2.  A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.

Authors:  Ophelia Q P Yin; Brian Tomlinson; Albert H L Chow; Moses S S Chow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

4.  Population pharmacokinetic analysis of simvastatin and its active metabolite with the characterization of atypical complex absorption kinetics.

Authors:  Seok-Joon Jin; Kyun-Seop Bae; Sang-Heon Cho; Jin-Ah Jung; Unjib Kim; Sangmin Choe; Jong-Lyul Ghim; Yook-Hwan Noh; Hyun-Jung Park; Hee-Sun Kim; Hyeong-Seok Lim
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

5.  In vivo release kinetics of octreotide acetate from experimental polymeric microsphere formulations using oil/water and oil/oil processes.

Authors:  Santos B Murty; Qui Wei; B C Thanoo; Patrick P DeLuca
Journal:  AAPS PharmSciTech       Date:  2004-09-30       Impact factor: 3.246

6.  The use of a sum of inverse Gaussian functions to describe the absorption profile of drugs exhibiting complex absorption.

Authors:  Chantal Csajka; David Drover; Davide Verotta
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

7.  Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles.

Authors:  A B Suttle; G M Pollack; K L Brouwer
Journal:  Pharm Res       Date:  1992-03       Impact factor: 4.200

8.  Applications and simulations of a discontinuous oral absorption pharmacokinetic model.

Authors:  J W Witcher; F D Boudinot
Journal:  Pharm Res       Date:  1996-11       Impact factor: 4.200

9.  Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics.

Authors:  Lien Ngo; Hee-Doo Yoo; Phuong Tran; Hea-Young Cho; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-18       Impact factor: 2.745

10.  Pharmacokinetic analysis of an oral sustained-release diltiazem preparation using multifraction absorption models.

Authors:  K Murata; K Noda
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.